Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy Stock

Showing results (151-160 of 322) with videos related to

Pageof 33
Sort By:
Leukemia Research|December 3, 2019
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trialElias Jabbour, Nicola Gökbuget, Anjali Advani, et al.
Blood Advances|June 21, 2019
Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioningKoen van Besien, Andrew Artz, Richard E Champlin, et al.
Haematologica|October 1, 2013
Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance)Meir Wetzler, Dorothy Watson, Wendy Stock, et al.
Blood Advances|January 4, 2018
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 studyDaniel J DeAngelo, Wendy Stock, Anthony S Stein, et al.
Journal of Hematology & Oncology|May 3, 2024
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure modelKellie J Archer, Han Fu, Krzysztof Mrózek, et al.
Blood Advances|September 9, 2024
A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosisChenyu Lin, Anand A Patel, Dezheng Huo, et al.
Cancer|November 2, 2023
Alliance A151945: Accrual and characteristics of adolescent and young adult patients in Alliance trials from 2000 to 2017Shoshana M Rosenberg, Shaylene McCue, Jun He, et al.
Leukemia & Lymphoma|October 29, 2009
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemiaThomas S Lin, Wendy Stock, Huiping Xu, et al.
American Journal of Hematology|January 10, 2019
Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicinElias Jabbour, Anjali S Advani, Matthias Stelljes, et al.
Bone Marrow Transplantation|January 30, 2020
Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survivalShawn Kothari, Andrew S Artz, Sang Mee Lee, et al.
Pageof 33

Showing results (151-160 of 322) with videos related to

Sort By:
Pageof 33
Leukemia Research|December 3, 2019
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trialElias Jabbour, Nicola Gökbuget, Anjali Advani, et al.
Blood Advances|June 21, 2019
Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioningKoen van Besien, Andrew Artz, Richard E Champlin, et al.
Haematologica|October 1, 2013
Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance)Meir Wetzler, Dorothy Watson, Wendy Stock, et al.
Blood Advances|January 4, 2018
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 studyDaniel J DeAngelo, Wendy Stock, Anthony S Stein, et al.
Journal of Hematology & Oncology|May 3, 2024
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure modelKellie J Archer, Han Fu, Krzysztof Mrózek, et al.
Blood Advances|September 9, 2024
A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosisChenyu Lin, Anand A Patel, Dezheng Huo, et al.
Cancer|November 2, 2023
Alliance A151945: Accrual and characteristics of adolescent and young adult patients in Alliance trials from 2000 to 2017Shoshana M Rosenberg, Shaylene McCue, Jun He, et al.
Leukemia & Lymphoma|October 29, 2009
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemiaThomas S Lin, Wendy Stock, Huiping Xu, et al.
American Journal of Hematology|January 10, 2019
Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicinElias Jabbour, Anjali S Advani, Matthias Stelljes, et al.
Bone Marrow Transplantation|January 30, 2020
Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survivalShawn Kothari, Andrew S Artz, Sang Mee Lee, et al.
Pageof 33